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Abstract
Background Knowledge about treatment status can influence effects measured in trials when subjective scales are used.
Objective The aim of this study was to compare subjective outcomes with objective outcomes of conventional and atypical 
antipsychotics for neuropsychiatric symptoms (NPS) in dementia.
Methods We performed a meta-epidemiological study of 38 randomized, placebo-controlled trials. For effectiveness, we used 
change in NPS and response rate as subjective outcomes, while overall dropout and additional psychotropic use were used 
as objective outcomes. For side effects, extrapyramidal symptoms (EPS) and somnolence were used as subjective outcomes, 
while dropout due to adverse events, medication use for EPS, and participants falling were used as objective outcomes.
Results Conventional antipsychotics reduced NPS more than placebo (standardized mean difference [SMD] − 0.36, 95% 
confidence interval [CI] − 0.49 to − 0.23), as did atypical antipsychotics (SMD − 0.14, 95% CI − 0.19 to − 0.08). Response 
rates in the drug groups were also higher. Overall dropout did not differ between conventional antipsychotics and placebo 
(odds ratio [OR] 1.03, 95% CI 0.77–1.37) or atypical antipsychotics and placebo (OR 1.01, 95% CI 0.89–1.14). Further-
more, additional psychotropic use did not differ. The risk of EPS was higher for conventional (OR 2.93, 95% CI 2.04–4.22) 
and atypical antipsychotics (OR 1.52, 95% CI 1.23–1.88) versus placebo, as was the risk of somnolence and dropout due to 
adverse events, but medication use for EPS, as well as risk of falls, was not.
Conclusions The effectiveness of antipsychotics for NPS in dementia based on subjective scales was not confirmed using 
objective outcomes, in contrast to the increased risk of side effects.
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 h.j.luijendijk@umcg.nl
1 Department of General Practice and Elderly Care Medicine, 
University Medical Centre Groningen, University 
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Key Points 
According to objective measures, antipsychotics do not 
effectively reduce neuropsychiatric symptoms in demen-
tia, and increase the risk of side effects.
Trials and reviews of trials should use objectively meas-
ured outcomes to enhance the validity of the results.
1 Introduction
Doctors often prescribe antipsychotics to treat neuropsy-
chiatric symptoms (NPS) in patients with dementia [1, 
2]. The prevalence of NPS is 70–90% in institutionalized 
patients with dementia [3, 4], with the most common symp-
toms being aggression, agitation and apathy [5]. NPS have 
a great impact on the quality of life of patients, informal 
caregivers and health professionals [6, 7]. More than 60% of 
patients with NPS use psychotropic drugs, and antipsychot-
ics account for almost two-thirds of this use [8, 9].
Knowledge about treatment status can influence the meas-
urement of efficacy and side effects when they are estab-
lished using subjective rating scales [10]. Such measurement 
error can bias the trial results (information bias, observer 
bias) as efficacy might be overestimated, and the risk of side 
effects underestimated [11].
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Trials use placebo tablets to blind participants, caregiv-
ers and assessors for treatment status to avoid measurement 
error [12]; however, this way of blinding is not always suc-
cessful. Treatment status can sometimes be guessed, for 
instance if the active drug has specific side effects [13]. A 
systematic review about blinding in randomized controlled 
trials (RCTs) among psychiatric patients showed that 
patients in the active treatment group more often correctly 
guessed the treatment status than the patient receiving pla-
cebo [10]. This also applied to the investigators. In particu-
lar, a trial comparing alprazolam with placebo in patients 
with anxiety disorders showed that side effects were associ-
ated with correctly guessing treatment status [14].
Likewise, in a study about the effects of caffeine on cogni-
tive performance, false positive feedback about performance 
made patients believe they received caffeine pills instead of 
the placebo they actually received [15]. These patients had 
faster reaction times than patients who did not get feedback 
and believed they had received placebo [15]. It is possible 
that the effect of antipsychotics on NPS in dementia is sys-
tematically overestimated due to partial unblinding by the 
specific side effects of antipsychotics, such as extrapyrami-
dal symptoms (EPS).
If treatment efficacy and side effects can be over- or 
underestimated due to measurement error, objective out-
comes may provide more valid results. Examples of objec-
tive outcome measures are the use of rescue medication, 
and medication for side effects. In addition, overall dropout 
is an objective measure of effectiveness in terms of the bal-
ance between efficacy and acceptability [16]. For instance, 
meta-analyses of trials comparing paroxetine against pla-
cebo for major depression have shown a statistically signifi-
cant effect on depressive symptoms, but the proportion of 
patients who discontinued treatment for any reason was not 
different between the groups [16].
In trials about antipsychotics for NPS in dementia, more 
objective outcome measures for efficacy and side effects are 
available, which may be established with less measurement 
error. Examples are dropout for any reason, dropout due to 
adverse events, and use of additional psychotropic medica-
tion, rescue medication, or medication to treat EPS. The aim 
of our study was to assess the effectiveness and side effects 
of antipsychotics in randomized placebo-controlled trials for 
NPS in patients with dementia using subjective and objec-
tive outcome measures.
2  Methods
2.1  Search Strategy and Study Selection
We made a list of antipsychotics (conventional and atypi-
cal) from the websites of the World Health Organization, 
US Food and Drug Administration (FDA) and Wikipedia 
to enable this search [17–19]. To identify trials, we used 
three sources. First, two authors (TAH, HJL) searched the 
Pubmed, Cinahl, EMBASE and Cochrane Library electronic 
databases using the following keywords: ‘generic name of 
atypical/conventional antipsychotic’ and trial and dementia. 
We restricted the keywords related to drug name to title and 
abstract. Second, we searched the references of published 
systematic reviews by hand. We identified these meta-anal-
yses using the abovementioned electronic databases. Third, 
we looked for RCTs in trial registration websites using the 
same keywords if possible; otherwise, we only used the term 
‘dementia’. Lastly, we searched the European Medicines 
Agency (EMA) and FDA websites for eligible trials. For 
a previous project, we were also able to search for atypi-
cal antipsychotic trials in the Dutch Medicines Evaluation 
Board databases. Titles and abstracts of potential eligible 
studies were retrieved from Pubmed, with the last search 
being run in June 2019.
Randomized, placebo-controlled trials that investigated 
the efficacy of orally administered conventional or atypi-
cal antipsychotics in patients with NPS and dementia were 
included, while studies with more than one drug in an 
intervention arm were excluded. There were no restrictions 
with respect to dosage, flexible or fixed dosing of the active 
treatment, trial duration, publication date and language. Two 
authors (TAH, HJL) determined definitive eligibility.
2.2  Data Extraction
Two authors (EJV, TAH) independently extracted data on 
study characteristics and outcomes. Disagreements were 
resolved by discussion and consensus with the third author 
(HJL). We extracted general study characteristics, including 
setting, type of dementia, type of NPS (agitation, psycho-
sis, or diverse NPS), type of antipsychotic treatment (con-
ventional or atypical), and the total number of randomized 
patients in the treatment groups.
As subjective measures of effectiveness, we extracted the 
mean change in symptoms from baseline to the end of the 
trial (or endpoint if not available). Changes on symptom 
scales were extracted for the specific indication for which 
the antipsychotic was tested in the trial. For instance, if the 
trial enrolled patients with psychosis, the extracted results 
were specific for psychosis, such as the psychosis subscale of 
the Neuropsychiatric Inventory (NPI). The standard devia-
tion (SD) of the difference was either extracted or calculated 
using the p-value, t-value or confidence interval (CI) [20]. 
We also extracted the number of patients with a clinically 
relevant improvement on the subjective symptom scales (as 
defined by the authors) or the number of patients with any 
improvement on clinical rating scales. Response rates as 
measured using both types of scales were combined [16]. As 
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an objective measure of effectiveness, we extracted the num-
ber of patients who received new additional psychotropic 
medication, including rescue medication, during the study. 
The number of patients who dropped out due to any reason 
was used as an objective measure of acceptability [21].
In our review of side effects, we focused on EPS and som-
nolence because these are prevalent and severe side effects 
of antipsychotics. In most studies, EPS was measured using 
a specific rating scale, e.g. the Simpson–Angus scale. Som-
nolence, also called sedation or drowsiness, was measured 
using a specific rating scale, such as the visual analogue 
sedation scale, or spontaneous reports. We extracted the 
number of patients with EPS and somnolence, measured 
using these subjective measurement instruments. As an 
objective measure of side effects, we extracted the number 
of patients who dropped out due to adverse events, and who 
used medication for EPS. Although the level of EPS and 
the use of medication for EPS are related, the distinction 
between these outcomes is the degree to which their meas-
urement is sensitive to error. EPS can be rated as more or 
less severe than they really are, whereas the use of medica-
tion for EPS is a verifiable fact. In addition, at the request 
of a reviewer, we extracted the number of participants who 
had fallen during the study because it is an objectively 
measurable outcome and a potential consequence of EPS 
and somnolence.
When multiple intervention groups with various dosages 
of a drug were tested in a trial, we calculated an average of 
the combined groups for all outcomes. The protocol and 
data extraction form can be obtained from the correspond-
ing author.
2.3  Data Analysis
First, we calculated the pooled effectiveness of antipsychot-
ics for NPS in dementia in terms of the standardized mean 
difference (SMD). SMDs were calculated with a 95% CI. 
Second, we calculated an odds ratio (OR), with a 95% CI, for 
all other outcome measures of effectiveness and side effects. 
We used fixed-effect models if heterogeneity (presented as 
I2) was lower than 40% and the p value was > 0.05 for the 
Chi-square test; otherwise, we used random-effect models.
We performed the meta-analyses separately for conven-
tional and atypical antipsychotics because effectiveness 
and the risk of side effects are assumed to differ between 
these groups. Hence, all comparisons of a conventional drug 
versus placebo were pooled, as were all comparisons of an 
atypical drug versus placebo. Therefore, the placebo group 
from a trial that tested both types of antipsychotics was used 
in both meta-analyses. To assess whether the pooled effects 
of conventional and atypical antipsychotics differed signifi-
cantly, we used the standard error (SE) of the difference 
of the pooled SMD and OR between treatment groups to 
calculate z using the Z-formula, and then p.
3  Results
3.1  Study Characteristics
We identified 2768 hits using our search criteria, with 65 
studies seeming to be potentially eligible. Twenty studies 
were excluded for various reasons, such as only including 
patients with Lewy body dementia, study medication was 
not orally administered, or the trial did not use a placebo 
group [22–41]. We identified 45 eligible studies, but five 
studies did not provide data regarding any of the outcomes 
of interest and could not be used in our meta-analyses [42, 
43 and NCT02168920, NCT00041678, NCT00036114], and 
two were ongoing [NCT03548584, NCT03620981]. The 
remaining 38 trials with 7726 participants were included 
in our analyses [21, 44–80]. Figure 1 shows the results of 
our search.
Table 1 shows the study characteristics of the included 
studies. The majority of studies investigated haloperidol (8 
trials) [55, 71–73, 75, 77–79], risperidone (10 trials) [21, 
48–50, 53, 56, 57, 60, 61, 71], quetiapine (5 trials) [21, 
59, 63, 64, 73] or olanzapine (7 trials) [21, 47, 51–53, 58, 
60] with placebo. Three studies tested both a conventional 
antipsychotic and an atypical antipsychotic versus placebo 
[71–73]. Of the 38 studies, 12 had psychosis as an indication 
[44, 49, 55, 57, 58, 60–62, 65, 69, 73, 80], 11 had agitation 
[53, 56, 59, 63, 67, 70, 72, 76, 77, 79], 14 had diverse NPS 
[21, 45–48, 50–52, 64, 66, 71, 74, 75, 78] and one study 
did not report the type of NPS [54]. Twenty-four studies 
were performed in patients living in nursing homes [45, 46, 
48–51, 56, 58–63, 65, 67–74, 76], seven in hospitals [44, 
55, 58, 66, 72, 75, 79], seven as outpatients [21, 60, 67, 70, 
77, 78, 80] and six studies did not report the setting [47, 
52–54, 57, 64].
Subjective measures of effectiveness were reported more 
frequently than objective measures (Table 2). In particular, 
the use of additional medication for NPS, use of medication 
for EPS, and number of participants with falls were poorly 
reported. As a result, some of the meta-analyses yielded 
large CIs.
3.2  Effectiveness
Conventional antipsychotics had a statistically significant 
but small effect on the reduction of NPS in dementia: SMD 
− 0.36 (95% CI − 0.49 to − 0.23). The response rate was 
also significantly higher in the conventional antipsychot-
ics group than in the placebo group (OR 1.82; 95% CI 
1.39–2.38). However, there was no statistically significant 
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effect of conventional antipsychotics on NPS in dementia 
compared with placebo when measured using objective 
outcome measures. The risk of the use of additional psy-
chotropic medication was numerically lower but not statis-
tically significant in the conventional antipsychotic versus 
placebo groups (OR 0.82, 95% CI 0.55–1.22). Further-
more, overall dropout did not differ between conventional 
antipsychotics and placebo (OR 1.03, 95% CI 0.77–1.37).
For atypical antipsychotics, there was a statistically 
significant but clinically negligible decrease of NPS in 
dementia compared with placebo: SMD − 0.14 (95% CI 
− 0.19 to − 0.08). However, the response rate was signifi-
cantly higher in the atypical antipsychotics group than in 
the placebo group (OR 1.53; 95% CI 1.32–1.76). Again, 
there was also no effect of atypical antipsychotics on NPS 
in dementia compared with placebo when measured using 
objective outcome measures. Additionally, the risk of the 
use of additional psychotropic medication was numeri-
cally lower but not statistically significant compared with 
placebo (OR 0.87, 95% CI 0.73–1.03). Overall dropout did 
not differ between the atypical antipsychotics and placebo 
groups (OR 1.01, 95% CI 0.89–1.14).
As reported above, both conventional and atypical antip-
sychotics had an effect on NPS in dementia when measured 
subjectively. We tested whether these effects differed statisti-
cally. Conventional antipsychotics reduced NPS more than 
atypical antipsychotics compared with placebo (SMD − 0.36 
vs. − 0.14; p < 0.001), but the response rates did not differ 
statistically (OR 1.82 versus 1.53; p = 0.267). There was 
no statistical difference between conventional and atypical 
antipsychotics when measured using the objective outcome 
measures of overall dropout (OR 1.03 vs. 1.01; p = 0.897) 
or use of additional psychotropic medication (OR 0.82 vs. 
0.87; p = 0.803).
3.3  Side Effects
When measured using subjective scales for EPS, conven-
tional antipsychotics were associated with significantly 
more EPS than placebo (OR 2.93, 95% CI 2.04–4.22). 
Somnolence also occurred significantly more often in the 
642 hits excluded
based on title/ abstract
940 hits excluded 
based on title/ abstract
712 hits included and 647 duplicate hits removed (the same hit, and multiple articles/ conference abstracts of the same RCT)
65 RCTs included for full text review
20 RCTs excluded: 
Systematic review: Rabinowitz 2007 
Not randomized: Cahn 1973
No placebo group: Ather 1986, Bamrah 1999, Birkett 1972, Martin-Cook 2005, Engstrand 
1967, Spagnolo 1983, Sheng 2004, Sun 2004
No parallel groups/ cross-over data only: Barton 1966, Devanand 1989, Tewfik 1970
Multiple drugs in same arm: Meguro 2004
Non-oral medication: Rappaport 2009, Meehan 2002
Not in Alzheimer or vascular dementia: Lehman 1972, Hamilton 1962b, Kurlan 2007
In dementia but without neuropsychiatric symptoms: Kennedy 200545 RCTs eligible for this study
4 no published/ available data on any outcome: Auer 1996 (haloperidol, thioridazine), 
NCT02168920 (aripiprazole), NCT00041678 (aripiprazole); NCT00036114 (aripiprazole)
1 no data on outcomes of this study: Stotsky 1984 (thioridazine)
2 ongoing: NCT03548584 (brexpiprazole), NCT03620981 (brexpiprazole)38 RCTs used in this study
1474 Potentially relevant hits 





606 references of systematic 
reviews and meta-analyses 
checked
661 references checked on 17 
national trial registration 
websites
27 from FDA, EMA, and 
(national) MEB database
449 hits excluded 
based on title/ abstract
25 hits excluded based 
on title/ abstract
Fig. 1  Flow diagram of the literature search and study selection. EMA European Medicines Agency, US FDA United States Food and Drug 
Administration, MEB Medicines Evaluation Board, RCT randomized controlled trial
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Table 1  General characteristics of randomized, placebo-controlled trials
AD Alzheimer’s disease, CBS chronic brain syndrome, HOS hospital, MIX mixed dementia (Alzheimers/vascular), NH nursing home, NPS neu-
ropsychiatric symptoms, OUTP outpatients, Ph pharmaceutical company, NR not reported, VAS vascular dementia
a In particular, aggression
b Results only reported for the 1 mg, 2 mg and placebo groups (total n = 413)
Author (year) Antipsychotic drug Type of dementia Type of NPS Setting N Dura-
tion, 
weeks
Conventional antipsychotics (10 trials)
Hamilton (1962) [44] Trifluoperazine CBS Psychosis HOS 27 8
Sugerman (1964) [55] Haloperidol CBS Psychosis HOS 18 6
Rada (1976) [66] Thiothixene CBS Diverse NPS HOS 42 4
Barnes (1982) [74] Thioridazine, loxapine Dementia Diverse NPS NH 53 8
Petrie (1982) [75] Haloperidol, loxapine Dementia Diverse NPS HOS 61 8
Finkel (1995) [76] Thiotixene Dementia Agitation NH 33 12
Auchus (1997) [77] Haloperidol AD Agitation OUTP 12 6
Devanand (1998) [78] Haloperidol AD Diverse NPS OUTP 66 6
Teri (2000) [79] Haloperidol AD Agitation HOS 70 16
Pollock (2002) [45] Perphenazine AD, VAS and MIX Diverse NPS NH 54 25
Atypical antipsychotics (25 trials)
Pfizer Ph (1993) [46] Ziprasidone AD and VAS Diverse NPS NH 23 4
Satterlee (1995) [47] Olanzapine AD Diverse NPS NR 238 8
Janssen Ph (1997) [48] Risperidone AD Diverse NPS NH 39 4
Katz (1999) [50] Risperidone AD, VAS and MIX Diverse NPS NH 625 12
Street (2000) [51] Olanzapine AD Diverse NPS NH 206 6
Howanitz (2001) [52] Olanzapine VAS Diverse NPS NR 16 6
Herz (2002) [53] Risperidone, olanzapine AD Agitation NR 29 6
Novartis Ph (2002) [54] Iloperidone AD, VAS and MIX NR NR 15 4
Brodaty (2003) [56] Risperidone AD, VAS and MIX Agitationa NH 345 12
Janssen Ph (2003) [49] Risperidone AD Psychosis NH 18 8
De Deyn (2004) [58] Olanzapine AD Psychosis NH and HOS 652 10
Ballard (2005) [59] Quetiapine AD Agitation NH 62 6
De Deyn (2005) [80] Aripiprazole AD Psychosis OUTP 208 10
Deberdt (2005) [60] Risperidone, olanzapine AD, VAS and MIX Psychosis NH–OUTP 494 10
Janssen Ph (2005) [57] Risperidone AD Psychosis NR 33 8
Mintzer (2006) [61] Risperidone AD Psychosis NH 473 8
Schneider (2006) [21] Risperidone, olanzapine, 
quetiapine
AD Diverse NPS OUTP 421 36
Mintzer (2007) [62] Aripiprazole AD Psychosis NH 487 10
Zhong (2007) [63] Quetiapine AD and VAS Agitation NH 333 10
Paleacu (2008) [64] Quetiapine AD Diverse NPS NR 40 6
Streim (2008) [65] Aripiprazole AD Psychosis NH 256 10
Otsuka Ph (2017a) [67] Brexpiprazoleb AD Agitation NH 433 12
Otsuka Ph (2017b) [68] Brexpiprazole AD Agitation NH–OUTP 270 12
Ballard (2018) [69] Pimavanserin AD Psychosis NH 181 12
ACADIA Ph (2018) [70] Pimavanserin AD Agitation NH–OUTP 111 12
Conventional and atypical antipsychotic drug (3 trials)
De Deyn (1999) [71] Haloperidol, risperidone AD, VAS and MIX Diverse NPS NH 334 12
Allain (2000) [72] Haloperidol, tiapride AD, VAS and MIX Agitation NH–HOS 306 3
Tariot (2006) [73] Haloperidol, quetiapine AD Psychosis NH 284 10
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conventional antipsychotics group than in the placebo group 
(OR 4.07, 95% CI 1.80–9.20). When measured using objec-
tive outcome measures, the risk of dropout due to adverse 
events was also significantly higher in the conventional 
antipsychotics group than in the placebo group (OR 1.78; 
95%CI 1.05–3.00). Medication for EPS was used more often 
in conventional antipsychotics compared with placebo, but 
the difference was not statistically significantly different (OR 
1.67, 95% CI 0.64–4.35). The risk of falls was not increased 
(OR 1.02, 95% CI 0.55–1.91).
In the atypical antipsychotics group, the risk of EPS was 
significantly higher compared with placebo (OR 1.51, 95% 
CI 1.25–1.82), and somnolence also occurred significantly 
more often in the atypical antipsychotics group than in the 
placebo group (OR 2.69, 95% CI 1.99–3.62). When meas-
ured using objective outcome measures for side effects, the 
risk of dropout due to adverse events was also significantly 
higher with atypical antipsychotics than with placebo (OR 
1.51, 95% CI 1.25–1.83). The risk of using medication for 
EPS did not differ between the atypical antipsychotics and 
placebo groups (OR 0.95, 95% CI 0.55–1.62), and nor did 
the risk of falls (OR 0.99, 95% CI 0.80–1.22).
We also tested whether the risk of side effects differed 
between conventional and atypical antipsychotics versus 
placebo. The risk of EPS was higher in the conventional 
antipsychotics group than in the atypical antipsychotics 
group versus placebo (OR 2.93 vs. 1.52; p = 0.002), but the 
risk of somnolence was not (OR 4.07 vs. 2.69; p = 0.347). 
There was no statistically significant difference between con-
ventional and atypical antipsychotics when measured using 
the objective outcome measures of dropout due to adverse 
events (OR 1.78 versus 1.51; p = 0.569), the use of medica-
tion for EPS (OR 1.67 vs. 0.95; p = 0.312), or risk of falls 
(OR 1.02 vs. 0.99; p = 0.920).
Three placebo-controlled studies tested both the new-gen-
eration atypical antipsychotics and haloperidol, the standard 
(conventional) drug at the time, against placebo [69–71]. 
In a post hoc sensitivity analysis without these studies, the 
risk of dropout due to adverse events was no longer statisti-
cally significantly increased for conventional antipsychotics 
versus placebo. In addition, the response rate and risk of 
somnolence for these drugs became close to those of atypi-
cal drugs versus placebo. All other results did not change 
substantially, or could not be reliably interpreted due to too 
few studies.
4  Discussion
We performed a meta-epidemiological study of 38 trials 
testing conventional and atypical antipsychotics for NPS 
in dementia. Antipsychotics were effective when measured 
using subjective measures, but not when using objective 
measures. Likewise, conventional antipsychotics were more 
effective than atypical antipsychotics when measured subjec-
tively, but this difference did not hold when measured objec-
tively. For both drug groups, EPS and somnolence occurred 
more often in the antipsychotic groups than in the placebo 
group when measured using subjective scales, as did dropout 
due to adverse events, which can be measured objectively. 
Table 2  Effects of antipsychotics on the subjective and objective outcomes in patients with neuropsychiatric symptoms in dementia
AP antipsychotics, CI confidence interval, EPS extrapyramidal symptoms, OR odds ratio, SMD standardized mean difference
a Random-effect model (all others fixed-effect model)
Conventional AP vs. placebo (13 trials) Atypical AP vs. placebo (28 trials) ORconventional 
vs.  ORatypical
No. of trials OR unless indicated 
otherwise (95% CI)




Change in symptoms, SMD 10 − 0.36 (− 0.49 to − 0.23) 23 − 0.14 (− 0.19 to − 0.08) < 0.001
Response rate 11 1.82 (1.39–2.38) 13 1.53 (1.32–1.76) 0.267
Effectiveness: objective outcomes
Overall dropout 11 1.03 (0.77–1.37) 26 1.01 (0.89–1.14) 0.897
Use of additional psychotropic medication 3 0.82 (0.55–1.22) 9 0.87 (0.73–1.03) 0.803
Side effects: subjective outcomes
EPS 6 2.93 (2.04–4.22) 17 1.52 (1.23–1.88) 0.002
Somnolencea 6 4.07 (1.80–9.20) 18 2.69 (1.99–3.62) 0.347
Side effects: objective outcomes
Dropout due to adverse events 6 1.78 (1.05–3.00) 24 1.51 (1.25–1.83) 0.569
Use of medication for EPS 2 1.67 (0.64–4.35) 3 0.95 (0.55–1.62) 0.312
Falls 1 1.02 (0.55–1.91) 11 0.99 (0.80–1.22) 0.920
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The use of medication for EPS seemed to be higher for con-
ventional antipsychotics but not for atypical antipsychotics, 
but power was too low to yield definitive estimates. The risk 
of falls was not increased for either type of antipsychotic.
4.1  Subjective Versus Objective Measures
We found that subjective measures of effectiveness sug-
gested that conventional antipsychotics had a small effect 
on NPS in dementia, and atypical antipsychotics had a very 
small (negligible) effect. If these were unbiased estimates 
of the true effects, we would have expected them to be con-
firmed using estimates based on objective measures. How-
ever, according to the outcomes of overall dropout and use 
of additional psychotropic medication, antipsychotics were 
not effective for NPS in dementia. Prior meta-analyses also 
found that although conventional and atypical antipsychotics 
decreased subjectively measured symptoms, dropout rates 
did not differ between the treatment and placebo groups 
[81–83]. Despite the latter finding, the conclusions of these 
meta-analyses were that antipsychotics were efficacious for 
NPS in dementia.
There are a number of explanations for the difference in 
findings based on subjective and objective measures of effec-
tiveness of antipsychotics for NPS in dementia. First, biased 
outcome reporting, i.e. systematic measurement error, can 
occur when patients or caregivers can guess which treatment 
they receive despite blinding [10]. Patients and caregivers 
might also be more willing to complete the trial if they or 
staff believe the patient to be in the treatment group [15]. 
Likewise, staff might be more tended to motivate patients 
and caregivers when patients are thought to receive active 
treatment. In case of antipsychotics, typical side effects such 
as EPS can give away treatment status and lead to these 
effects. It is also possible that, apart from bias, antipsychot-
ics are efficacious, especially in patients with side effects 
because benefits and harms stem from the same neurotrans-
mitter inhibition, or, in the case of somnolence, the reduction 
of NPS is the direct effect of the side effect.
We found that EPS and somnolence occurred more often 
in the conventional and atypical antipsychotics groups com-
pared with placebo, as assessed using subjective measures. 
These findings correspond with those of prior meta-anal-
yses [81–86]. In addition, the risk of EPS was higher for 
conventional antipsychotics than atypical antipsychotics 
compared with placebo, which also corresponds with prior 
meta-analytic findings [87, 88]. Part of this finding might 
be explained by higher doses of haloperidol used in older 
haloperidol trials.
Remarkably though, dropout due to adverse events did 
not differ statistically between conventional and atypical 
antipsychotics in our study. It is likely EPS and somno-
lence were not the only adverse events leading to dropout. 
Other less prevalent side effects or serious adverse events 
might have played a role. For example, meta-analyses 
of trials have shown that atypical antipsychotics had an 
increased risk of death in patients with dementia, but con-
ventional antipsychotics did not [89, 90]. Atypical antipsy-
chotics also increased the risk of cerebrovascular accidents 
in trials among patients with Alzheimer’s disease [84]. 
In addition, although dropout is an objective measure, 
knowledge of the treatment can also influence dropout, 
but probably much less than the usual subjectively meas-
ured outcomes.
In addition, the use of medication for EPS was not 
statistically significantly increased for conventional and 
atypical antipsychotics versus placebo. However, lack of 
power is a problem in both comparisons, with only 2 of 
16 trials about conventional antipsychotics and 3 of 31 tri-
als about atypical antipsychotics reporting this outcome. 
In addition, the use of medicines for EPS will not cover 
all patients who develop EPS because physicians might 
rather discontinue treatment or lower the antipsychotic 
dose. Possible selective reporting, with studies reporting 
these outcomes having more favorable results, renders a 
correct interpretation of our finding even more difficult.
Finally, the risk of falls was not increased for either type 
of antipsychotic, even though the risks of EPS and somno-
lence, which can lead to falls, were. Possibly, antipsychotic 
use might especially increase the rate of falls, but the mean 
number of falls per participant was not reported in the 
studies. In addition, none of the trials identified falls as an 
outcome a priori, therefore it is not clear whether falls had 
been recorded systematically, if at all.
4.2  Strengths and Limitations
As far as we know, this is the first meta-analysis that inves-
tigated the effects of antipsychotics for NPS in dementia 
using subjective and objective outcome measures. In addi-
tion, we performed a broad search covering unpublished 
data, which resulted in the inclusion of a relatively large 
number of trials compared with prior reviews.
Unfortunately, most of the older trials that we included, 
namely the studies testing conventional antipsychotics, 
did not report all the variables we were interested in. 
In particular, the objective outcome measures of use of 
additional psychotropic medication, use of medication for 
EPS, and falls were often missing. If this was the result of 
selective reporting, the risk of side effects might have been 
underestimated in our analyses using these measures. In 
addition, due to the lack of data, reliability of some of the 
pooled effects was low.
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5  Conclusions
The effectiveness of antipsychotics for NPS in dementia 
based on commonly used subjective scales could not be 
confirmed using objective measures. Subjective measures 
of side effects suggested that conventional antipsychotics 
had a higher risk than atypical antipsychotics, but objec-
tive measures did not. Therefore, future trials and reviews 
regarding psychotropic medication for NPS in dementia need 
to address potential information bias by regularly including 
objective measures. Guidelines need to base recommenda-
tions on the effects established, preferably using objective 
outcome measures.
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